Incidence and time course of everolimus-related adverse events in postmenopausal women with hormone receptor-positive advanced breast cancer: insights from BOLERO-2

In the BOLERO-2 trial, everolimus (EVE), an inhibitor of mammalian target of rapamycin, demonstrated significant clinical benefit with an acceptable safety profile when administered with exemestane (EXE) in postmenopausal women with hormone receptor-positive (HR+) advanced breast cancer. We report o...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Annals of oncology 2014-04, Vol.25 (4), p.808-815
Hauptverfasser:	Rugo, H.S., Pritchard, K.I., Gnant, M., Noguchi, S., Piccart, M., Hortobagyi, G., Baselga, J., Perez, A., Geberth, M., Csoszi, T., Chouinard, E., Srimuninnimit, V., Puttawibul, P., Eakle, J., Feng, W., Bauly, H., El-Hashimy, M., Taran, T., Burris, H.A.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult advanced breast cancer Aged Aged, 80 and over Antineoplastic agents Biological and medical sciences Breast Neoplasms - drug therapy Breast Neoplasms - genetics Breast Neoplasms - pathology Disease-Free Survival Drug-Related Side Effects and Adverse Reactions - classification Drug-Related Side Effects and Adverse Reactions - pathology Everolimus Female Gynecology. Andrology. Obstetrics Humans mammalian target of rapamycin (mTOR) Mammary gland diseases Medical sciences Middle Aged Multiple tumors. Solid tumors. Tumors in childhood (general aspects) Neoplasm Staging Original Pharmacology. Drug treatments Postmenopause safety Sirolimus - administration & dosage Sirolimus - adverse effects Sirolimus - analogs & derivatives TOR Serine-Threonine Kinases - genetics Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!